Recent Publications


  1. Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski J, Auberger P, Wei S, Fenaux P, Santini V, List A.Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes. 2017;102(12):2015-20. Epub 2017/10/07. doi: 10.3324/haematol.2016.158857. PubMed PMID: 28983059

 

  1. McGraw K, List A.Erythropoietin Receptor Signaling and Lipid Rafts. Vitamins and hormones. 2017;105:79-100. Epub 2017/06/21. doi: 10.1016/bs.vh.2017.02.002. PubMed PMID: 28629526.

 

  1. Zhang L, McGraw KL, Sallman DA, List AF.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leukemia & lymphoma.2017;58(8):1777-90. Epub 2016/12/15. doi: 10.1080/10428194.2016.1266625. PubMed PMID: 27967292.

 

  1. Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016;128(25):2960-75. Epub 2016/10/16. doi: 10.1182/blood-2016-07-730556. PubMed PMID: 27737891; PMCID: PMC5179338.

 

  1. Sallman DA, Cluzeau T, Basiorka AA, List A. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Frontiers in oncology.2016;6:151. Epub 2016/07/06. doi: 10.3389/fonc.2016.00151. PubMed PMID: 27379212; PMCID: PMC4909736.

 

  1. Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.Cancer Res. 2016;76(12):3531-40. Epub 2016/05/20. doi: 10.1158/0008-5472.can-15-1756. PubMed PMID: 27197154; PMCID: PMC4911265.

 

  1. McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. 2016;101(8):e320-3. Epub 2016/04/16. doi: 10.3324/haematol.2016.143214. PubMed PMID: 27081179; PMCID: PMC4967580.

 

  1. McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Sole F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015;6(33):34437-45. Epub 2015/09/30. doi: 10.18632/oncotarget.5255. PubMed PMID: 26416416; PMCID: PMC4741464.

 

  1. Sallman DA, Wei S, List A. PP2A: The Achilles Heal in MDS with 5q Deletion.Frontiers in oncology. 2014;4:264. Epub 2014/10/09. doi: 10.3389/fonc.2014.00264. PubMed PMID: 25295231; PMCID: PMC4172014.

 

  1. McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.PloS one. 2014;9(12):e114249. Epub 2014/12/04. doi: 10.1371/journal.pone.0114249. PubMed PMID: 25469886; PMCID: PMC4254997.

 

  1. Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(40):16127-32. Epub 2013/09/18. doi: 10.1073/pnas.1311055110. PubMed PMID: 24043769; PMCID: PMC3791697.

 

  1. Jerez A, Clemente MJ, Makishima H, Rajala H, Gomez-Segui I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, LeBlanc F, Lagstrom S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP, Jr., Maciejewski JP. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. 2013;122(14):2453-9. Epub 2013/08/09. doi: 10.1182/blood-2013-04-494930. PubMed PMID: 23926297; PMCID: PMC3790512.

 

  1. Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A.Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.  2013;32(9):1110-20. Epub 2012/04/25. doi: 10.1038/onc.2012.139. PubMed PMID: 22525275; PMCID: PMC3751397.

 

  1. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A.A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(31):12974-9. Epub 2009/05/28. doi: 10.1073/pnas.0811267106. PubMed PMID: 19470455; PMCID: PMC2722346. 

 

 

Bibliography